BC Extra | May 16, 2018
Company News

Management tracks: Novartis, Aileron

Novartis AG (NYSE:NVS; SIX:NOVN) said General Counsel Felix Ehrat will retire, effective June 1, in light of Novartis' payments to a consultancy owned by Michael Cohen. "As a co-signatory with our former CEO, I take...
BioCentury | Jan 6, 2017
Product Development

Viral vulnerability

Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc. is treating virus-associated cancers by forcing them to re-express latent viral proteins that...
BC Week In Review | Jul 28, 2014
Company News

Signal Genetics management update

Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Hired: Tamara Seymour as CFO, formerly CFO of HemaQuest Pharmaceuticals Inc. ; she succeeds Robert Johnson, who resigned as CFO, effective Aug. 4...
BC Week In Review | Jun 17, 2013
Clinical News

HQK-1001: Completed Phase IIb enrollment

HemaQuest completed enrollment of 77 patients in a double-blind, placebo-controlled, international Phase IIb trial evaluating twice-daily oral HQK-1001 for 48 weeks. The compound has Orphan Drug designation in the U.S. and Europe to treat sickle...
BC Week In Review | Mar 19, 2012
Financial News

HemaQuest financial update

HemaQuest raised $13 million in an extension of a series B round, bringing the total raised in the round to $29 million. Existing investors Aberdare Ventures; De Novo Ventures; Forward Ventures; Latterell Venture Partners; and...
BC Extra | Mar 13, 2012
Financial News

HemaQuest raises $13M in series B extension

HemaQuest Pharmaceuticals Inc. (San Diego, Calif.) raised $13 million in an extension of a series B round, bringing the total raised in the round to $29 million. Existing investors Aberdare Ventures; De Novo Ventures; Forward...
BC Week In Review | Sep 19, 2011
Clinical News

HQK-1001: Completed Phase II enrollment

HemaQuest completed enrollment of 52 patients in an open-label, dose-escalation, international Phase II trial evaluating 30, 40 and 50 mg/kg oral HQK-1001 daily for 26 weeks. The compound has Orphan Drug designation in the U.S....
BC Week In Review | May 2, 2011
Clinical News

HQK-1001: Phase II started

HemaQuest began an open-label, dose-escalation, international Phase II trial to evaluate 30, 40 and 50 mg/kg oral HQK-1001 daily for 26 weeks in about 50 patients. The compound has Orphan Drug designations in the U.S....
BC Week In Review | Dec 6, 2010
Company News

HemaQuest management update

HemaQuest Pharmaceuticals Inc. , San Diego, Calif.   Business: Hematology   Hired: Richard Ghalie as CMO; John Longenecker as president, CEO and a director; and Tamara Seymour as CFO; all of whom formerly served at Favrille...
BC Extra | Dec 4, 2010
Company News

HemaQuest names Longenecker CEO

Hematology company HemaQuest Pharmaceuticals Inc. (San Diego, Calif.) hired John Longenecker as president, CEO and a director. Longenecker is the former president and CEO of Favrille Inc. HemaQuest also hired Richard Ghalie as CMO and...
Items per page:
1 - 10 of 21
BC Extra | May 16, 2018
Company News

Management tracks: Novartis, Aileron

Novartis AG (NYSE:NVS; SIX:NOVN) said General Counsel Felix Ehrat will retire, effective June 1, in light of Novartis' payments to a consultancy owned by Michael Cohen. "As a co-signatory with our former CEO, I take...
BioCentury | Jan 6, 2017
Product Development

Viral vulnerability

Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc. is treating virus-associated cancers by forcing them to re-express latent viral proteins that...
BC Week In Review | Jul 28, 2014
Company News

Signal Genetics management update

Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Hired: Tamara Seymour as CFO, formerly CFO of HemaQuest Pharmaceuticals Inc. ; she succeeds Robert Johnson, who resigned as CFO, effective Aug. 4...
BC Week In Review | Jun 17, 2013
Clinical News

HQK-1001: Completed Phase IIb enrollment

HemaQuest completed enrollment of 77 patients in a double-blind, placebo-controlled, international Phase IIb trial evaluating twice-daily oral HQK-1001 for 48 weeks. The compound has Orphan Drug designation in the U.S. and Europe to treat sickle...
BC Week In Review | Mar 19, 2012
Financial News

HemaQuest financial update

HemaQuest raised $13 million in an extension of a series B round, bringing the total raised in the round to $29 million. Existing investors Aberdare Ventures; De Novo Ventures; Forward Ventures; Latterell Venture Partners; and...
BC Extra | Mar 13, 2012
Financial News

HemaQuest raises $13M in series B extension

HemaQuest Pharmaceuticals Inc. (San Diego, Calif.) raised $13 million in an extension of a series B round, bringing the total raised in the round to $29 million. Existing investors Aberdare Ventures; De Novo Ventures; Forward...
BC Week In Review | Sep 19, 2011
Clinical News

HQK-1001: Completed Phase II enrollment

HemaQuest completed enrollment of 52 patients in an open-label, dose-escalation, international Phase II trial evaluating 30, 40 and 50 mg/kg oral HQK-1001 daily for 26 weeks. The compound has Orphan Drug designation in the U.S....
BC Week In Review | May 2, 2011
Clinical News

HQK-1001: Phase II started

HemaQuest began an open-label, dose-escalation, international Phase II trial to evaluate 30, 40 and 50 mg/kg oral HQK-1001 daily for 26 weeks in about 50 patients. The compound has Orphan Drug designations in the U.S....
BC Week In Review | Dec 6, 2010
Company News

HemaQuest management update

HemaQuest Pharmaceuticals Inc. , San Diego, Calif.   Business: Hematology   Hired: Richard Ghalie as CMO; John Longenecker as president, CEO and a director; and Tamara Seymour as CFO; all of whom formerly served at Favrille...
BC Extra | Dec 4, 2010
Company News

HemaQuest names Longenecker CEO

Hematology company HemaQuest Pharmaceuticals Inc. (San Diego, Calif.) hired John Longenecker as president, CEO and a director. Longenecker is the former president and CEO of Favrille Inc. HemaQuest also hired Richard Ghalie as CMO and...
Items per page:
1 - 10 of 21